Drug Trial Radar · NCT06200103
Schedule De-Escalation of 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer
Last checked: Nov 20, 2026Latest source record: Aug 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Suspended
Enrollment
236
Planned (sponsor's estimate)
Start
May 3, 2024
Primary completion
Dec 31, 2029
Study completion Dec 31, 2029
Sponsor
- Lead sponsor
- Mayo ClinicAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jan 10, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase II trial studies how to improve the usage of Lu 177 vipivotide tetraxetan (177Lu-prostate-specific membrane antigen \[PSMA\]-617) for treating patients with castration-resistant prostate cancer that has spread from where it first started (primary site), to other places in the body (metastatic) utilizing a treatment pause after 5 cycles of therapy versus standard continuous treatment for 6 cycles. Lutetium is a radioligand therapy (RLT). RLT uses a small molecule (in this case 177Lu-PSMA-617) that carries a radioactive component to destroy tumor cells. When lutetium is injected into the body, it attaches to the PSMA receptor found on tumor cells. After lutetium attaches to the PSMA receptor, its radiation component destroys the tumor cell. Giving 177Lu-PSMA-617 for 5 cycles versus 6 cycles may better treat patients with metastatic castrate resistant prostate cancer.
Conditions
- Castration-Resistant Prostate Carcinoma
- Stage IVB Prostate Cancer AJCC v8
Interventions
Biospecimen CollectionProcedure
Undergo blood sample collection
Bone ScanProcedure
Undergo bone scan
Clinical ObservationOther
Undergo active monitoring
Computed TomographyProcedure
Undergo SPECT/CT or PET/CT
Gallium Ga 68 GozetotideOther
Given IV
Lutetium Lu 177 Vipivotide TetraxetanDrug
Given IV
Positron Emission TomographyProcedure
Undergo PET/CT
Questionnaire AdministrationOther
Ancillary studies
Single Photon Emission Computed TomographyProcedure
Undergo SPECT/CT
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free survivalTime frame: Up to 5 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Mayo Clinic in Rochester
Rochester, Minnesota
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.